Sutro Biopharma STRO Investment and other (expense) income, net
Investment and other (expense) income, net at other companies
Other financials
Where this comes from
Reported directly by Sutro Biopharma in its filing.
Tagged under the XBRL concept us-gaap:InvestmentIncomeNonoperating.
The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sutro Biopharma's investment and other (expense) income, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sutro Biopharma's investment and other (expense) income, net?
- Sutro Biopharma (STRO) reported investment and other (expense) income, net of $1.64M in Q1 2026.
- How has Sutro Biopharma's investment and other (expense) income, net changed year-over-year?
- Sutro Biopharma's investment and other (expense) income, net decreased by 48.7% year-over-year, from $3.19M to $1.64M.
- What is the long-term trend for Sutro Biopharma's investment and other (expense) income, net?
- Over 4 years (2021 to 2025), Sutro Biopharma's investment and other (expense) income, net has grown at a 100.1% compound annual growth rate (CAGR), from $577K to $9.25M.
- What does investment and other (expense) income, net mean?
- This metric represents income generated from non-operating activities, such as interest earned on cash balances, marketable securities, or other financial investments. It reflects the company's ability to generate returns on its idle capital outside of its core biopharmaceutical research and development operations. Investors monitor this to assess the yield on the company's treasury management strategy.